Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma.
Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, Ravikumar S, Srivastava S, Tian X, Poon RT, Fan ST, Luk JM, Dan YY, Salto-Tellez M, Chai L, Tenen DG. Yong KJ, et al. Among authors: lim js. N Engl J Med. 2013 Jun 13;368(24):2266-76. doi: 10.1056/NEJMoa1300297. N Engl J Med. 2013. PMID: 23758232 Free PMC article.
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.
Kong LR, Mohamed Salleh NAB, Ong RW, Tan TZ, Syn NL, Goh RM, Fhu CW, Tan DSW, Iyer NG, Kannan S, Verma CS, Lim YC, Soo R, Ho J, Huang Y, Lim JSJ, Yan BJ, Nga ME, Lim SG, Koeffler HP, Lee SC, Kappei D, Hung HT, Goh BC. Kong LR, et al. Nat Commun. 2020 Mar 25;11(1):1556. doi: 10.1038/s41467-020-15318-5. Nat Commun. 2020. PMID: 32214092 Free PMC article.
Targeting Cell Metabolism as Cancer Therapy.
Ngoi NYL, Eu JQ, Hirpara J, Wang L, Lim JSJ, Lee SC, Lim YC, Pervaiz S, Goh BC, Wong ALA. Ngoi NYL, et al. Antioxid Redox Signal. 2020 Feb 10;32(5):285-308. doi: 10.1089/ars.2019.7947. Epub 2019 Dec 16. Antioxid Redox Signal. 2020. PMID: 31841375 Review.
Outcome after neoadjuvant chemotherapy in Asian breast cancer patients.
Lim LY, Miao H, Lim JS, Lee SC, Bhoo-Pathy N, Yip CH, Taib NA, Chan P, Tan EY, Lim SH, Lim GH, Woo E, Tan YS, Lee JA, Wong M, Tan PH, Ong KW, Wong FY, Yap YS, Hartman M. Lim LY, et al. Among authors: lim sh, lim gh, lim js. Cancer Med. 2017 Jan;6(1):173-185. doi: 10.1002/cam4.985. Epub 2016 Dec 20. Cancer Med. 2017. PMID: 28000426 Free PMC article.
Emerging biomarkers for PD-1 pathway cancer therapy.
Lim JS, Sundar R, Chénard-Poirier M, Lopez J, Yap TA. Lim JS, et al. Biomark Med. 2017 Jan;11(1):53-67. doi: 10.2217/bmm-2016-0228. Epub 2016 Dec 12. Biomark Med. 2017. PMID: 27936870 Review.
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Pascual J, Lim JSJ, Macpherson IR, Armstrong AC, Ring A, Okines AFC, Cutts RJ, Herrera-Abreu MT, Garcia-Murillas I, Pearson A, Hrebien S, Gevensleben H, Proszek PZ, Hubank M, Hills M, King J, Parmar M, Prout T, Finneran L, Malia J, Swales KE, Ruddle R, Raynaud FI, Turner A, Hall E, Yap TA, Lopez JS, Turner NC. Pascual J, et al. Among authors: lim jsj. Cancer Discov. 2021 Jan;11(1):92-107. doi: 10.1158/2159-8290.CD-20-0553. Epub 2020 Sep 21. Cancer Discov. 2021. PMID: 32958578
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers.
Lee SC, Shimasaki N, Lim JSJ, Wong A, Yadav K, Yong WP, Tan LK, Koh LP, Poon MLM, Tan SH, Ow SGW, Bharwani L, Yap YS, Foo MZQ, Coustan-Smith E, Sundar R, Tan HL, Chong WQ, Kumarakulasinghe NB, Lieow JLM, Koe PJX, Goh BC, Campana D. Lee SC, et al. Clin Cancer Res. 2020 Sep 1;26(17):4494-4502. doi: 10.1158/1078-0432.CCR-20-0768. Epub 2020 Jun 10. Clin Cancer Res. 2020. PMID: 32522887 Clinical Trial.
1,363 results